Current Approaches to Bone-targeted Therapy in Genitourinary Malignancies

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2012 Oct 2

PMID 23024704

Authors

Peter F Mulders

Affiliations

Soon will be listed here.

Abstract

Bone metastases in patients with genitourinary cancers are associated with increased risk for skeletal-related events including pathologic fractures, spinal cord compression, and the requirement for surgery or palliative radiotherapy to bone. The nitrogen-containing bisphosphonate zoledronic acid and the monoclonal antibody against RANK, denosumab, are approved for the prevention of skeletal-related events in genitourinary cancers. These agents have different mechanisms of action and pharmacokinetic profiles, and while both are effective in reducing the risk of skeletal-related events, other clinical effects differ. There is evidence for direct and indirect anticancer activity with zoledronic acid from preclinical studies and emerging data from clinical studies suggesting an effect on patient survival. Potential anticancer mechanisms include inhibition of angiogenesis, enhanced immune surveillance via stimulation of γδ T cells, and reduction of circulating tumor cells. A synergistic effect of chemotherapy plus zoledronic acid has also been suggested. Further research is ongoing regarding the roles of these antiresorptive therapies in patients with bone metastases or at high risk for malignant spread to skeletal sites.

References

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View

Zwolak P, Manivel J, Jasinski P, Kirstein M, Dudek A, Fisher J . Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am. 2010; 92(1):162-8. DOI: 10.2106/JBJS.H.01679. View

Lipton A, Zheng M, Seaman J . Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003; 98(5):962-9. DOI: 10.1002/cncr.11571. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux N . B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006; 169(3):987-98. PMC: 1698808. DOI: 10.2353/ajpath.2006.060180. View

Ullen A, Schwarz S, Lennartsson L, Kalkner K, Sandstrom P, Costa F . Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol. 2008; 43(2):98-103. DOI: 10.1080/00365590802475904. View

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Saad F, Lipton A, Cook R, Chen Y, Smith M, Coleman R . Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-7. DOI: 10.1002/cncr.22991. View

Janni W, Vogl F, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J . Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res. 2011; 17(9):2967-76. DOI: 10.1158/1078-0432.CCR-10-2515. View

10.

Solomayer E, Gebauer G, Hirnle P, Janni W, Luck H, Becker S . Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. 2012; 23(9):2271-2277. DOI: 10.1093/annonc/mdr612. View

11.

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

12.

Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C . Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol. 2006; 176(5):2255-61. DOI: 10.1016/j.juro.2006.07.053. View

13.

Neville-Webbe H, Evans C, Coleman R, Holen I . Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006; 27(2):92-103. DOI: 10.1159/000092489. View

14.

Garcia J, Rosenberg J, Weinberg V, Scott J, Frohlich M, Park J . Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 2007; 99(3):519-24. DOI: 10.1111/j.1464-410X.2007.06659.x. View

15.

Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K . Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2004; 47(1):31-9. DOI: 10.1016/j.lungcan.2004.06.003. View

16.

Vogel C, Yanagihara R, Wood A, Schnell F, Henderson C, Kaplan B . Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004; 9(6):687-95. DOI: 10.1634/theoncologist.9-6-687. View

17.

Green J, Clezardin P . The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 2010; 37 Suppl 1:S3-11. DOI: 10.1053/j.seminoncol.2010.06.003. View

18.

Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View

19.

Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A . Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2010; 48(1):160-6. DOI: 10.1016/j.bone.2010.09.008. View

20.

Brown J, Cook R, Major P, Lipton A, Saad F, Smith M . Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005; 97(1):59-69. DOI: 10.1093/jnci/dji002. View